

Press release
Cyxone AB (publ)
559020-5471
August 17, 2018

The logo for Cyxone, consisting of the word "CYXONE" in a bold, blue, sans-serif font.

Cyxone changes Certified Adviser to Mangold Fondkommission AB

Cyxone AB (publ) announced today that the company changes Certified Adviser.

Cyxone has entered an agreement with Mangold Fondkommission AB regarding the service as Certified Adviser. Mangold Fondkommission AB will act as the Certified Adviser as of August 21, 2018. Until then, Erik Penser Bank will continue to act as Certified Adviser to the company.

Contact

Cyxone AB (publ)
Kjell G. Stenberg, CEO
Tel: +46 (0) 723 816 168
Email: kjell.g.stenberg@cyxone.com
Adelgatan 21
221 22 Malmö
Sweden
www.cyxone.com

About Cyxone

Cyxone AB is a clinical stage biotech company with a portfolio of immunomodulating drugs for the treatment of autoimmune diseases such as multiple sclerosis (MS) and rheumatoid arthritis (RA). The company's drug portfolio is based on two technological pillars in the form of oral molecules and cyclotide-based drugs that inhibit key processes in the body's cells that are typically associated with various immune-related disorders. Cyxone's technologies have the potential to address an unmet need and provide new effective and safe medicines that can improve the quality of life for patients affected by autoimmune diseases. The company has two drug candidates, T20K for MS in a preclinical program and Rabeximod for RA in clinical phase II-program. Cyxone's Certified Adviser on the Nasdaq First North is Erik Penser Bank, +46 (0)8 4638000.
www.cyxone.com